Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dr. Reddy's Laboratories Ltd ADR
(NY:
RDY
)
75.21
+0.43 (+0.58%)
Official Closing Price
Updated: 7:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dr. Reddy's Laboratories Ltd ADR
< Previous
1
2
3
4
5
6
Next >
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
March 23, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
March 23, 2023
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
Via
News Direct
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development
March 22, 2023
Houston-based Coya Therapeutics (NASDAQ: COYA) has entered into a partnership with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a world-leading pharmaceutical company based in India.
Via
Benzinga
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302
March 21, 2023
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302
Via
News Direct
Intercept Settles Ocaliva Litigation With Reddy's Lab
August 17, 2022
Via
Benzinga
India Based Pharma Companies In Race To Buy Athenex, Shares Surge
August 05, 2022
Via
Benzinga
Eton Pharma Shares Tick Higher After Offloading Hospital Products
June 24, 2022
Via
Benzinga
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302
March 21, 2023
By Kenneth Adams, Benzinga
Via
TheNewswire.com
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy's Laboratories To License And Commercialize COYA 302
March 20, 2023
Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced a worldwide agreement with Dr. Reddy’s Laboratories Limited.
Via
Benzinga
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases
March 20, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Dr. Reddy's Seeks Gaining Foothold In Women's Health Via Mayne Pharma's U.S. Generic Prescription Deal
February 27, 2023
Via
Benzinga
Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio
February 27, 2023
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s included in Bloomberg Gender-Equality Index for the 6th year in a row and S&P Global’s Sustainability Yearbook for the 3rd year
February 08, 2023
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
The 3 Most Undervalued Stocks in India for Your February Buy List
January 31, 2023
These are a few of the top undervalued stocks in India, providing investors with exposure to strong growth outlooks in the coming years.
Via
InvestorPlace
Dr. Reddy's Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market
January 27, 2023
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years
January 25, 2023
Intercept entered a deal with Amneal, likely lining up a series of new settlements.
Via
Investor's Business Daily
Dr. Reddy’s successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe
January 20, 2023
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Journey Medical Touts Positive PK Data For Bacterial Infection Candidate
December 20, 2022
Via
Benzinga
Dr. Reddy’s Successfully Completes Phase 1 Study of DRL_TC, a Proposed Biosimilar of Tocilizumab
December 19, 2022
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Novartis Fails To Prevent Generic Competition For Its Blockbuster Multiple Sclerosis Drug
October 14, 2022
The U.S. Supreme Court rejected Novartis AG's (NYSE: NVS) effort to block the launch of generic versions of its multiple sclerosis drug Gilenya.
Via
Benzinga
World Economic Forum Recognises Dr. Reddy’s Hyderabad Factory as Part of its Global Lighthouse Network
October 11, 2022
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity
September 07, 2022
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Is Sanofi A Buy, Despite Recent Stumbles?
August 19, 2022
Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
August 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
August 05, 2022
Good morning! We're starting off the last day of trading this week with a breakdown of the biggest pre-market stock movers for Friday!
Via
InvestorPlace
Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S.
July 29, 2022
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market
July 27, 2022
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market
July 22, 2022
From
Dr. Reddy’s Laboratories Ltd. 500124
Via
Business Wire
Dr. Reddy's Laboratories Announces the Launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. Market
July 08, 2022
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership with EQRx
July 05, 2022
From
Aurigene Discovery Technologies Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.